Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jan Klijn

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Genes & Molecular Sequences

Chemicals & Drugs

Concepts & Ideas

Physiology

Geographic Areas

Netherlands

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kriege Mieke; Seynaeve Caroline; Meijers-Heijboer Hanne; Collee J Margriet; Menke-Pluymers Marian B E; Bartels Carina C M; Tilanus-Linthorst Madeleine M A; Blom Jannet; Huijskens Elisabeth; Jager Agnes; van den Ouweland Ans; van Geel Bert; Hooning Maartje J; Brekelmans Cecile T M; Klijn Jan G M
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Wasielewski Marijke; den Bakker Michael A; van den Ouweland Ans; Meijer-van Gelder Marion E; Portengen Henk; Klijn Jan G M; Meijers-Heijboer Hanne; Foekens John A; Schutte Mieke
CHEK2 1100delC and male breast cancer in the Netherlands.
Jansen Maurice P H M; Ruigrok-Ritstier Kirsten; Dorssers Lambert C J; van Staveren Iris L; Look Maxime P; Meijer-van Gelder Marion E; Sieuwerts Anieta M; Helleman Jozien; Sleijfer Stefan; Klijn Jan G M; Foekens John A; Berns Els M J J
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jan Klijn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kriege Mieke; Seynaeve Caroline; Meijers-Heijboer Hanne; Collee J Margriet; Menke-Pluymers Marian B E; Bartels Carina C M; Tilanus-Linthorst Madeleine M A; Blom Jannet; Huijskens Elisabeth; Jager Agnes; van den Ouweland Ans; van Geel Bert; Hooning Maartje J; Brekelmans Cecile T M; Klijn Jan G M
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3764-71.
2009: Wasielewski Marijke; den Bakker Michael A; van den Ouweland Ans; Meijer-van Gelder Marion E; Portengen Henk; Klijn Jan G M; Meijers-Heijboer Hanne; Foekens John A; Schutte Mieke
CHEK2 1100delC and male breast cancer in the Netherlands.
Breast cancer research and treatment 2009;116(2):397-400.
2009: Jansen Maurice P H M; Ruigrok-Ritstier Kirsten; Dorssers Lambert C J; van Staveren Iris L; Look Maxime P; Meijer-van Gelder Marion E; Sieuwerts Anieta M; Helleman Jozien; Sleijfer Stefan; Klijn Jan G M; Foekens John A; Berns Els M J J
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Breast cancer research and treatment 2009;116(2):263-71.
2009: Zhang Yi; Martens John W M; Yu Jack X; Jiang John; Sieuwerts Anieta M; Smid Marcel; Klijn Jan G M; Wang Yixin; Foekens John A
Copy number alterations that predict metastatic capability of human breast cancer.
Cancer research 2009;69(9):3795-801.
2009: Kok Marleen; Linn Sabine C; Van Laar Ryan K; Jansen Maurice P H M; van den Berg Teun M; Delahaye Leonie J M J; Glas Annuska M; Peterse Johannes L; Hauptmann Michael; Foekens John A; Klijn Jan G M; Wessels Lodewyk F A; Van't Veer Laura J; Berns Els M J J
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Breast cancer research and treatment 2009;113(2):275-83.
2009: Wasielewski Marijke; Hanifi-Moghaddam Pejman; Hollestelle Antoinette; Merajver Sofia D; van den Ouweland Ans; Klijn Jan G M; Ethier Stephen P; Schutte Mieke
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
Breast cancer research and treatment 2009;113(2):285-91.
2008: Hooning Maartje J; Aleman Berthe M P; Hauptmann Michael; Baaijens Margreet H A; Klijn Jan G M; Noyon Ruth; Stovall Marilyn; van Leeuwen Flora E
Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5561-8.
2008: Nimmrich Inko; Sieuwerts Anieta M; Meijer-van Gelder Marion E; Schwope Ina; Bolt-de Vries Joan; Harbeck Nadia; Koenig Thomas; Hartmann Oliver; Kluth Antje; Dietrich Dimo; Magdolen Viktor; Portengen Henk; Look Maxime P; Klijn Jan G M; Lesche Ralf; Schmitt Manfred; Maier Sabine; Foekens John A; Martens John W M
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Breast cancer research and treatment 2008;111(3):429-37.
2008: Helleman Jozien; Jansen Maurice P H M; Ruigrok-Ritstier Kirsten; van Staveren Iris L; Look Maxime P; Meijer-van Gelder Marion E; Sieuwerts Anieta M; Klijn Jan G M; Sleijfer Stefan; Foekens John A; Berns Els M J J
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5555-64.
2008: Foekens John A; Sieuwerts Anieta M; Smid Marcel; Look Maxime P; de Weerd Vanja; Boersma Antonius W M; Klijn Jan G M; Wiemer Erik A C; Martens John W M
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(35):13021-6.
2008: Kriege Mieke; Seynaeve Caroline; Meijers-Heijboer Hanne; Collee J Margriet; Menke-Pluymers Marian B E; Bartels Carina C M; Tilanus-Linthorst Madeleine M A; van den Ouweland Ans; van Geel Bert; Brekelmans Cecile T M; Klijn Jan G M
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Breast cancer research and treatment 2008;111(2):303-11.
2008: Wasielewski Marijke; Vasen Hans; Wijnen Juul; Hooning Maartje; Dooijes Dennis; Tops Carli; Klijn Jan G M; Meijers-Heijboer Hanne; Schutte Mieke
CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4989-94.
2008: Foekens John A; Wang Yixin; Martens John W M; Berns Els M J J; Klijn Jan G M
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
Drug discovery today 2008;13(11-12):481-7.
2008: Smid Marcel; Wang Yixin; Zhang Yi; Sieuwerts Anieta M; Yu Jack; Klijn Jan G M; Foekens John A; Martens John W M
Subtypes of breast cancer show preferential site of relapse.
Cancer research 2008;68(9):3108-14.
2008: de Bock Geertruida H; Jacobi Catharina E; Seynaeve Caroline; Krol-Warmerdam Elly M M; Blom Jannet; van Asperen Christi J; Cornelisse Cees J; Klijn Jan G M; Devilee Peter; Tollenaar Rob A E M; Brekelmans Cecile T M; van Houwelingen Johannes C
A family history of breast cancer will not predict female early onset breast cancer in a population-based setting.
BMC cancer 2008;8():203.
2007: Tilanus-Linthorst Madeleine M A; Obdeijn Inge-Marie; Hop Wim C J; Causer Petrina A; Leach Martin O; Warner Ellen; Pointon Linda; Hill Kimberley; Klijn Jan G M; Warren Ruth M L; Gilbert Fiona J
BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7357-62.
2007: Heemskerk-Gerritsen Bernadette A M; Brekelmans Cecile T M; Menke-Pluymers Marian B E; van Geel Albert N; Tilanus-Linthorst Madeleine M A; Bartels Carina C M; Tan Murly; Meijers-Heijboer Hanne E J; Klijn Jan G M; Seynaeve Caroline
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Annals of surgical oncology 2007;14(12):3335-44.
2007: van Oostrom Iris; Meijers-Heijboer Hanne; Duivenvoorden Hugo J; Bröcker-Vriends Annette H J T; van Asperen Christi J; Sijmons Rolf H; Seynaeve Caroline; Van Gool Arthur R; Klijn Jan G M; Tibben Aad
The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study.
Psycho-oncology 2007;16(12):1121-9.
2007: Bresser P J C; Van Gool A R; Seynaeve C; Duivenvoorden H J; Niermeijer M F; van Geel A N; Menke M; Klijn J G M; Tibben A
Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1641-5.
2007: Suter Thomas M; Procter Marion; van Veldhuisen Dirk J; Muscholl Michael; Bergh Jonas; Carlomagno Chiara; Perren Timothy; Passalacqua Rodolfo; Bighin Claudia; Klijn Jan G M; Ageev Fail T; Hitre Erika; Groetz Juergen; Iwata Hiroji; Knap Malgorzata; Gnant Michael; Muehlbauer Susanne; Spence Alison; Gelber Richard D; Piccart-Gebhart Martine J
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3859-65.
2007: Pieterse K; van Dooren S; Seynaeve C; Bartels C C M; Rijnsburger A J; de Koning H J; Klijn J G M; van Elderen T; Tibben A; Duivenvoorden H J
Passive coping and psychological distress in women adhering to regular breast cancer surveillance.
Psycho-oncology 2007;16(9):851-8.
2007: Wasielewski Marijke; Nagel Jord H A; Brekelmans Cecile; Klijn Jan G M; van den Ouweland Ans; Meijers-Heijboer Hanne; Schutte Mieke
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Breast cancer research and treatment 2007;104(2):153-7.
2007: Sieuwerts Anieta M; Usher Pernille A; Meijer-van Gelder Marion E; Timmermans Mieke; Martens John W M; Brünner Nils; Klijn Jan G M; Offenberg Hanne; Foekens John A
Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer.
Clinical chemistry 2007;53(7):1280-8.
2007: Desmedt Christine; Piette Fanny; Loi Sherene; Wang Yixin; Lallemand Françoise; Haibe-Kains Benjamin; Viale Giuseppe; Delorenzi Mauro; Zhang Yi; d'Assignies Mahasti Saghatchian; Bergh Jonas; Lidereau Rosette; Ellis Paul; Harris Adrian L; Klijn Jan G M; Foekens John A; Cardoso Fatima; Piccart Martine J; Buyse Marc; Sotiriou Christos;
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3207-14.
2007: Kriege M; Brekelmans C T M; Peterse H; Obdeijn I M; Boetes C; Zonderland H M; Muller S H; Kok T; Manoliu R A; Besnard A P E; Tilanus-Linthorst M M A; Seynaeve C; Bartels C C M; Meijer S; Oosterwijk J C; Hoogerbrugge N; Tollenaar R A E M; de Koning H J; Rutgers E J T; Klijn J G M
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
Breast cancer research and treatment 2007;102(3):357-63.
2007: Loi Sherene; Haibe-Kains Benjamin; Desmedt Christine; Lallemand Françoise; Tutt Andrew M; Gillet Cheryl; Ellis Paul; Harris Adrian; Bergh Jonas; Foekens John A; Klijn Jan G M; Larsimont Denis; Buyse Marc; Bontempi Gianluca; Delorenzi Mauro; Piccart Martine J; Sotiriou Christos
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(10):1239-46.
2007: van Oostrom Iris; Meijers-Heijboer Hanne; Duivenvoorden Hugo J; Bröcker-Vriends Annette H J T; van Asperen Christi J; Sijmons Rolf H; Seynaeve Caroline; Van Gool Arthur R; Klijn Jan G M; Riedijk Samantha R; van Dooren Silvia; Tibben Aad
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships.
Psycho-oncology 2007;16(4):320-8.
2007: Hooning Maartje J; Botma Akke; Aleman Berthe M P; Baaijens Margreet H A; Bartelink Harry; Klijn Jan G M; Taylor Carolyn W; van Leeuwen Flora E
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
Journal of the National Cancer Institute 2007;99(5):365-75.
2007: Brekelmans C T M; Tilanus-Linthorst M M A; Seynaeve C; vd Ouweland A; Menke-Pluymers M B E; Bartels C C M; Kriege M; van Geel A N; Burger C W; Eggermont A M M; Meijers-Heijboer H; Klijn J G M
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
European journal of cancer (Oxford, England : 1990) 2007;43(5):867-76.
2007: Jansen Maurice P H M; Sieuwerts Anieta M; Look Maxime P; Ritstier Kirsten; Meijer-van Gelder Marion E; van Staveren Iris L; Klijn Jan G M; Foekens John A; Berns Els M J J
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):662-8.
2007: van Oostrom I; Meijers-Heijboer H; Duivenvoorden H J; Bröcker-Vriends A H J T; van Asperen C J; Sijmons R H; Seynaeve C; van Gool A R; Klijn J G M; Tibben A
Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study.
Clinical genetics 2007;71(1):35-42.
2007: Bresser P J C; Seynaeve C; Van Gool A R; Niermeijer M F; Duivenvoorden H J; van Dooren S; van Geel A N; Menke-Pluijmers M B; Klijn J G M; Tibben A
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy.
European journal of cancer (Oxford, England : 1990) 2007;43(1):95-103.
2007: van Oostrom Iris; Meijers-Heijboer Hanne; Duivenvoorden Hugo J; Bröcker-Vriends Annette H J T; van Asperen Christi J; Sijmons Rolf H; Seynaeve Caroline; Van Gool Arthur R; Klijn Jan G M; Tibben Aad
Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing.
European journal of cancer (Oxford, England : 1990) 2007;43(1):71-7.
2007: van Oostrom Iris; Meijers-Heijboer Hanne; Duivenvoorden Hugo J; Bröcker-Vriends Annette H J T; van Asperen Christi J; Sijmons Rolf H; Seynaeve Caroline; Van Gool Arthur R; Klijn Jan G M; Tibben Aad
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
Patient education and counseling 2007;65(1):58-68.
2007: Huijts Petra E A; Vreeswijk Maaike P G; Kroeze-Jansema Karin H G; Jacobi Catharina E; Seynaeve Caroline; Krol-Warmerdam Elly M M; Wijers-Koster Pauline M; Blom Jannet C; Pooley Karen A; Klijn Jan G M; Tollenaar Rob A E M; Devilee Peter; van Asperen Christi J
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.
Breast cancer research : BCR 2007;9(6):R78.
2007: Yu Jack X; Sieuwerts Anieta M; Zhang Yi; Martens John W M; Smid Marcel; Klijn Jan G M; Wang Yixin; Foekens John A
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer.
BMC cancer 2007;7():182.
2007: Piersma Djura; Themmen Axel P N; Look Maxime P; Klijn Jan G M; Foekens John A; Uitterlinden André G; Pols Huibert A P; Berns Els M J J
GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients.
Breast cancer research : BCR 2007;9(4):R51.
2007: Broeks Annegien; Braaf Linde M; Huseinovic Angelina; Nooijen Anke; Urbanus Jos; Hogervorst Frans B L; Schmidt Marjanka K; Klijn Jan G M; Russell Nicola S; Van Leeuwen Flora E; Van 't Veer Laura J
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
Breast cancer research : BCR 2007;9(2):R26.
2006: Thompson Deborah; Seal Sheila; Schutte Mieke; McGuffog Lesley; Barfoot Rita; Renwick Anthony; Eeles Rosalind; Sodha Nayanta; Houlston Richard; Shanley Susan; Klijn Jan; Wasielewski Marijke; Chang-Claude Jenny; Futreal P Andrew; Weber Barbara L; Nathanson Katherine L; Stratton Michael; Meijers-Heijboer Hanne; Rahman Nazneen; Easton Douglas F
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(12):2542-5.
2006: Hooning Maartje J; Dorresteijn Lucille D A; Aleman Berthe M P; Kappelle Arnoud C; Klijn Jan G M; Boogerd Willem; van Leeuwen Flora E
Decreased risk of stroke among 10-year survivors of breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(34):5388-94.
2006: Kriege Mieke; Brekelmans Cecile T M; Obdeijn Inge Marie; Boetes Carla; Zonderland Harmine M; Muller Sara H; Kok Theo; Manoliu Radu A; Besnard A Peter E; Tilanus-Linthorst Madeleine M A; Seynaeve Caroline; Bartels Carina C M; Kaas Reini; Meijer Siebren; Oosterwijk Jan C; Hoogerbrugge Nicoline; Tollenaar Rob A E M; Rutgers Emiel J T; de Koning Harry J; Klijn Jan G M
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
Breast cancer research and treatment 2006;100(1):109-19.
2006: Wasielewski Marijke; Elstrodt Fons; Klijn Jan G M; Berns Els M J J; Schutte Mieke
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast cancer research and treatment 2006;99(1):97-101.
2006: van Oostrom I; Meijers-Heijboer H; Duivenvoorden H J; Bröcker-Vriends A H J T; van Asperen C J; Sijmons R H; Seynaeve C; Van Gool A R; Klijn J G M; Tibben A
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(7):1090-5.
2006: Sieuwerts Anieta M; Look Maxime P; Meijer-van Gelder Marion E; Timmermans Mieke; Trapman Anita M A C; Garcia Roberto Rodriguez; Arnold Miranda; Goedheer Anneke J W; de Weerd Vanja; Portengen Henk; Klijn Jan G M; Foekens John A
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3319-28.
2006: Kriege Mieke; Brekelmans Cecile T M; Boetes Carla; Muller Sara H; Zonderland Harmine M; Obdeijn Inge Marie; Manoliu Radu A; Kok Theo; Rutgers Emiel J T; de Koning Harry J; Klijn Jan G M;
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Cancer 2006;106(11):2318-26.
2006: Bresser Paula J C; Seynaeve Caroline; Van Gool Arthur R; Brekelmans Cecile T; Meijers-Heijboer Hanne; van Geel Albert N; Menke-Pluijmers Marian B; Duivenvoorden Hugo J; Klijn Jan G M; Tibben Aad
Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.
Plastic and reconstructive surgery 2006;117(6):1675-82; discussion 1683-4.
2006: Smid Marcel; Wang Yixin; Klijn Jan G M; Sieuwerts Anieta M; Zhang Yi; Atkins David; Martens John W M; Foekens John A
Genes associated with breast cancer metastatic to bone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2261-7.
2006: Foekens John A; Atkins David; Zhang Yi; Sweep Fred C G J; Harbeck Nadia; Paradiso Angelo; Cufer Tanja; Sieuwerts Anieta M; Talantov Dmitri; Span Paul N; Tjan-Heijnen Vivianne C G; Zito Alfredo F; Specht Katja; Hoefler Heinz; Golouh Rastko; Schittulli Francesco; Schmitt Manfred; Beex Louk V A M; Klijn Jan G M; Wang Yixin
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1665-71.
2006: Hooning Maartje J; Aleman Berthe M P; van Rosmalen Agnes J M; Kuenen Marianne A; Klijn Jan G M; van Leeuwen Flora E
Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study.
International journal of radiation oncology, biology, physics 2006;64(4):1081-91.
2006: Brekelmans C T M; Seynaeve C; Menke-Pluymers M; Brüggenwirth H T; Tilanus-Linthorst M M A; Bartels C C M; Kriege M; van Geel A N; Crepin C M G; Blom J C; Meijers-Heijboer H; Klijn J G M
Survival and prognostic factors in BRCA1-associated breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):391-400.
2006: Yang F; Foekens J A; Yu J; Sieuwerts A M; Timmermans M; Klijn J G M; Atkins D; Wang Y; Jiang Y
Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways.
Oncogene 2006;25(9):1413-9.
2006: Tilanus-Linthorst Madeleine M A; Bartels Karina C M; Alves Celina; Bakri Bonnie; Crepin Ellen; van den Ouweland Ans; Klijn Jan G M; Meijers-Heijboer Hanne; Brekelmans Cecile T M
Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.
Breast cancer research and treatment 2006;95(2):117-23.
2006: de Bock G H; Mourits M J E; Schutte M; Krol-Warmerdam E M M; Seynaeve C; Blom J; Brekelmans C T M; Meijers-Heijboer H; van Asperen C J; Cornelisse C J; Devilee P; Tollenaar R A E M; Klijn J G M
Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():552-5.
2005: Jansen Maurice P H M; Foekens John A; Klijn Jan G M; Berns Els M J J
Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Journal of the National Cancer Institute 2005;97(24):1851-2; author reply 1852-3.
2005: Menke-Pluymers M B E; Seynaeve C; van Geel A N; Klijn J G M; Meijers-Heijboer E J; Eggermont A M M
[Preventive surgical prcedures for inherited risk of breast cancer]
Nederlands tijdschrift voor geneeskunde 2005;149(48):2663-7.
2005: Sieuwerts Anieta M; Meijer-van Gelder Marion E; Timmermans Mieke; Trapman Anita M A C; Garcia Roberto Rodriguez; Arnold Miranda; Goedheer Anneke J W; Portengen Henk; Klijn Jan G M; Foekens John A
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7311-21.
2005: van Asperen C J; Brohet R M; Meijers-Heijboer E J; Hoogerbrugge N; Verhoef S; Vasen H F A; Ausems M G E M; Menko F H; Gomez Garcia E B; Klijn J G M; Hogervorst F B L; van Houwelingen J C; van't Veer L J; Rookus M A; van Leeuwen F E;
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.
Journal of medical genetics 2005;42(9):711-9.
2005: Tilanus-Linthorst Madeleine M A; Kriege Mieke; Boetes Carla; Hop Wim C J; Obdeijn Inge-Marie; Oosterwijk Jan C; Peterse Hans L; Zonderland Harmine M; Meijer Sybren; Eggermont Alexander M M; de Koning Harry J; Klijn Jan G M; Brekelmans Cecile T M
Hereditary breast cancer growth rates and its impact on screening policy.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1610-7.
2005: van Dooren Silvia; Seynaeve Caroline; Rijnsburger Adriana J; Duivenvoorden Hugo J; Essink-Bot Marie-Louise; Tilanus-Linthorst Madeleine M A; Klijn Jan G M; de Koning Harry J; Tibben Aad
Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(10):1416-25.
2005: Martens John W M; Nimmrich Inko; Koenig Thomas; Look Maxime P; Harbeck Nadia; Model Fabian; Kluth Antje; Bolt-de Vries Joan; Sieuwerts Anieta M; Portengen Henk; Meijer-Van Gelder Marion E; Piepenbrock Christian; Olek Alexander; Höfler Heinz; Kiechle Marion; Klijn Jan G M; Schmitt Manfred; Maier Sabine; Foekens John A
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer research 2005;65(10):4101-17.
2005: Meeuwissen Paul A M; Seynaeve Caroline; Brekelmans Cecile T M; Meijers-Heijboer Hanne J; Klijn Jan G M; Burger Curt W
Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Gynecologic oncology 2005;97(2):476-82.
2005: Setyono-Han Buddy; Stürzebecher Jörg; Schmalix Wolfgang A; Muehlenweg Bernd; Sieuwerts Anieta M; Timmermans Mieke; Magdolen Viktor; Schmitt Manfred; Klijn Jan G M; Foekens John A
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Thrombosis and haemostasis 2005;93(4):779-86.
2005: Klijn J G M; de Vries E G E
[The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer]
Nederlands tijdschrift voor geneeskunde 2005;149(12):618-22.
2005: Helle S I; Mietlowski W; Guastalla J P; Szakolczai I; Bajetta E; Sommer H; Baltali E; Pinter T; Csepreghy M; Ottestad L; Boni C; Bryce C; Klijn J G M; Lønning P E
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
European journal of cancer (Oxford, England : 1990) 2005;41(5):694-701.
2005: Wang Yixin; Klijn Jan G M; Zhang Yi; Sieuwerts Anieta M; Look Maxime P; Yang Fei; Talantov Dmitri; Timmermans Mieke; Meijer-van Gelder Marion E; Yu Jack; Jatkoe Tim; Berns Els M J J; Atkins David; Foekens John A
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Lancet 2005;365(9460):671-9.
2005: Jansen Maurice P H M; Foekens John A; van Staveren Iris L; Dirkzwager-Kiel Maaike M; Ritstier Kirsten; Look Maxime P; Meijer-van Gelder Marion E; Sieuwerts Anieta M; Portengen Henk; Dorssers Lambert C J; Klijn Jan G M; Berns Els M J J
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):732-40.
2005: van Dooren Silvia; Seynaeve Caroline; Rijnsburger Adriana J; Duivenvoorden Hugo J; Essink-Bot Marie-Louise; Bartels Carina C M; Klijn Jan G M; de Koning Harry J; Tibben Aad
The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer.
Breast cancer research and treatment 2005;89(1):75-80.
2004: de Bock G H; Schutte M; Krol-Warmerdam E M M; Seynaeve C; Blom J; Brekelmans C T M; Meijers-Heijboer H; van Asperen C J; Cornelisse C J; Devilee P; Tollenaar R A E M; Klijn J G M
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
Journal of medical genetics 2004;41(10):731-5.
2004: Kruit W H J; Stoter G; Klijn J G M
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Anti-cancer drugs 2004;15(9):843-7.
2004: Dorssers Lambert C J; Grebenchtchikov Nicolai; Brinkman Arend; Look Maxime P; van Broekhoven Simone P J; de Jong Danielle; Peters Harry A; Portengen Henk; Meijer-van Gelder Marion E; Klijn Jan G M; van Tienoven Doorlene T H; Geurts-Moespot Anneke; Span Paul N; Foekens John A; Sweep Fred C G J
The prognostic value of BCAR1 in patients with primary breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6194-202.
2004: Dorssers Lambert C J; Grebenchtchikov Nicolai; Brinkman Arend; Look Maxime P; Klijn Jan G M; Geurts-Moespot Anneke; Span Paul N; Foekens John A; Sweep C G J Fred
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
Clinical chemistry 2004;50(8):1445-7.
2004: Kriege Mieke; Brekelmans Cecile T M; Boetes Carla; Besnard Peter E; Zonderland Harmine M; Obdeijn Inge Marie; Manoliu Radu A; Kok Theo; Peterse Hans; Tilanus-Linthorst Madeleine M A; Muller Sara H; Meijer Sybren; Oosterwijk Jan C; Beex Louk V A M; Tollenaar Rob A E M; de Koning Harry J; Rutgers Emiel J T; Klijn Jan G M;
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
The New England journal of medicine 2004;351(5):427-37.
2004: Meijer-van Gelder Marion E; Look Maxime P; Peters Harry A; Schmitt Manfred; Brünner Nils; Harbeck Nadia; Klijn Jan G M; Foekens John A
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Cancer research 2004;64(13):4563-8.
2004: Rijnsburger A J; Essink-Bot M L; van Dooren S; Borsboom G J J M; Seynaeve C; Bartels C C M; Klijn J G M; Tibben A; de Koning H J
Impact of screening for breast cancer in high-risk women on health-related quality of life.
British journal of cancer 2004;91(1):69-76.
2004: Seynaeve C; Verhoog L C; van de Bosch L M C; van Geel A N; Menke-Pluymers M; Meijers-Heijboer E J; van den Ouweland A M W; Wagner A; Creutzberg C L; Niermeijer M F; Klijn J G M; Brekelmans C T M
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1150-8.
2004: Schrohl Anne-Sofie; Holten-Andersen Mads N; Peters Harry A; Look Maxine P; Meijer-van Gelder Marion E; Klijn Jan G M; Brünner Nils; Foekens John A
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2289-98.
2004: Szabo Csilla I; Schutte Mieke; Broeks Annegien; Houwing-Duistermaat Jeanine J; Thorstenson Yvonne R; Durocher Francine; Oldenburg Rogier A; Wasielewski Marijke; Odefrey Fabrice; Thompson Deborah; Floore Arno N; Kraan Jaennelle; Klijn Jan G M; van den Ouweland Ans M W; Wagner Teresa M U; Devilee Peter; Simard Jacques; van 't Veer Laura J; Goldgar David E; Meijers-Heijboer Hanne
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
Cancer research 2004;64(3):840-3.
2004: Broeks Annegien; de Witte Lot; Nooijen Anke; Huseinovic Angelina; Klijn Jan G M; van Leeuwen Flora E; Russell Nicola S; van't Veer Laura J
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
Breast cancer research and treatment 2004;83(1):91-3.
2003: Oldenburg Rogier A; Kroeze-Jansema Karin; Kraan Jaennelle; Morreau Hans; Klijn Jan G M; Hoogerbrugge Nicoline; Ligtenberg Marjolein J L; van Asperen Christi J; Vasen Hans F A; Meijers Carel; Meijers-Heijboer Hanne; de Bock Truuske H; Cornelisse Cees J; Devilee Peter
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Cancer research 2003;63(23):8153-7.
2003: Harkes I C; Elstrodt F; Dinjens W N M; Molier M; Klijn J G M; Berns E M J J; Schutte M
Allelotype of 28 human breast cancer cell lines and xenografts.
British journal of cancer 2003;89(12):2289-92.
2003: van Oostrom Iris; Meijers-Heijboer Hanne; Lodder Litanja N; Duivenvoorden Hugo J; van Gool Arthur R; Seynaeve Caroline; van der Meer Conny A; Klijn Jan G M; van Geel Bert N; Burger Curt W; Wladimiroff Juriy W; Tibben Aad
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3867-74.
2003: van Asperen C J; Tollenaar R A E M; Krol-Warmerdam E M M; Blom J; Hoogendoorn W E; Seynaeve C M J C; Brekelmans C T M; Devilee P; Cornelisse C J; Klijn J G M; de Bock G H
Possible consequences of applying guidelines to healthy women with a family history of breast cancer.
European journal of human genetics : EJHG 2003;11(8):633-6.
2003: Lodder Litanja; Frets Petra G; Trijsburg R Willem; Klijn Jan G M; Seynaeve Caroline; Tilanus Madeleine M A; Bartels Carina C M; Meijers-Heijboer E Johanna; Verhoog Leon C; Niermeijer Martinus F
Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.
American journal of medical genetics. Part A 2003;119A(3):266-72.
2003: Berns Els M J J; Dirkzwager-Kiel Maaike J M; Kuenen-Boumeester Vibeke; Timmermans Mieke; Verhoog Leon C; van den Ouweland Ans M W; Meijer-Heijboer Hanne; Klijn Jan G M; van der Kwast Theo H
Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Breast cancer research and treatment 2003;79(1):121-7.
2003: Meijers-Heijboer Hanne; Brekelmans Cecile T M; Menke-Pluymers Marian; Seynaeve Caroline; Baalbergen Astrid; Burger Curt; Crepin Ellen; van den Ouweland Ans W M; van Geel Bert; Klijn Jan G M
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1675-81.
2003: Meijers-Heijboer Hanne; Wijnen Juul; Vasen Hans; Wasielewski Marijke; Wagner Anja; Hollestelle Antoinette; Elstrodt Fons; van den Bos Renate; de Snoo Anja; Fat Grace Tjon A; Brekelmans Cecile; Jagmohan Shantie; Franken Patrick; Verkuijlen Paul; van den Ouweland Ans; Chapman Pamela; Tops Carli; Möslein Gabriela; Burn John; Lynch Henry; Klijn Jan; Fodde Riccardo; Schutte Mieke
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.
American journal of human genetics 2003;72(5):1308-14.
2003: Berns Els M J J; Klijn Jan G M; Look Maxime P; Grebenchtchikov Nicolai; Vossen Rolf; Peters Harry; Geurts-Moespot Anneke; Portengen Henk; van Staveren Iris L; Meijer-van Gelder Marion E; Bakker Bert; Sweep Fred C G J; Foekens John A
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1253-8.
2003: Foekens J A; Ries Ch; Look M P; Gippner-Steppert C; Klijn J G M; Jochum M
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.
British journal of cancer 2003;88(7):1084-90.
2003: Schutte Mieke; Seal Sheila; Barfoot Rita; Meijers-Heijboer Hanne; Wasielewski Marijke; Evans D Gareth; Eccles Diana; Meijers Carel; Lohman Frans; Klijn Jan; van den Ouweland Ans; Futreal P Andrew; Nathanson Katherine L; Weber Barbara L; Easton Douglas F; Stratton Michael R; Rahman Nazneen;
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
American journal of human genetics 2003;72(4):1023-8.
2003: Nooij M A; de Haes J C J M; Beex L V A M; Wildiers J; Klijn J; Becquart D; Jassem J; Engelsman E; Duchateau L;
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences.
European journal of cancer (Oxford, England : 1990) 2003;39(5):614-21.
2003: Burger Herman; Foekens John A; Look Maxime P; Meijer-van Gelder Marion E; Klijn Jan G M; Wiemer Erik A C; Stoter Gerrit; Nooter Kees
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):827-36.
2003: Martens John W M; Sieuwerts Anieta M; Bolt-deVries Joan; Bosma Peter T; Swiggers Susan J J; Klijn Jan G M; Foekens John A
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Thrombosis and haemostasis 2003;89(2):393-404.
2003: Foekens John A; Ries Christian; Look Maxime P; Gippner-Steppert Cornelia; Klijn Jan G M; Jochum Marianne
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Cancer research 2003;63(2):337-41.
2002: Wagner A; Tops C; Wijnen J T; Zwinderman K; van der Meer C; Kets M; Niermeijer M F; Klijn J G M; Tibben A; Vasen H F A; Meijers-Heijboer H
Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation.
Journal of medical genetics 2002;39(11):833-7.
2002: Klijn J G M
LHRH-agonist versus chemotherapy in premenopausal breast cancer?
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 6():S45-6.
2002: Tilanus-Linthorst Madeleine; Verhoog Leon; Obdeijn Inge-Marie; Bartels Karina; Menke-Pluymers Marian; Eggermont Alexander; Klijn Jan; Meijers-Heijboer Hanne; van der Kwast Theo; Brekelmans Cecile
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
International journal of cancer. Journal international du cancer 2002;102(1):91-5.
2002: Contant C M E; Menke-Pluijmers M B E; Seynaeve C; Meijers-Heijboer E J; Klijn J G M; Verhoog L C; Tjong Joe Wai R; Eggermont A M M; van Geel A N
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2002;28(6):627-32.
2002: Harbeck Nadia; Kates Ronald E; Look Maxime P; Meijer-Van Gelder Marion E; Klijn Jan G M; Krüger Achim; Kiechle Marion; Jänicke Fritz; Schmitt Manfred; Foekens John A
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer research 2002;62(16):4617-22.
2002: Baum M; Budzar A U; Cuzick J; Forbes J; Houghton J H; Klijn J G M; Sahmoud T;
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Lancet 2002;359(9324):2131-9.
2002: Lodder Litanja N; Frets Petra G; Trijsburg R Willem; Meijers-Heijboer E Johanna; Klijn Jan G M; Seynaeve Caroline; van Geel Albertus N; Tilanus Madeleine M A; Bartels Carina C M; Verhoog Leon C; Brekelmans Cecile T M; Burger Curt W; Niermeijer Martinus F
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Breast cancer research and treatment 2002;73(2):97-112.
2002: Sieuwerts Anieta M; Martens John W M; Dorssers Lambert C J; Klijn Jan G M; Foekens John A
Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts.
Thrombosis and haemostasis 2002;87(4):674-83.
2001: Schuyer M; van der Burg M E; Henzen-Logmans S C; Fieret J H; Klijn J G; Look M P; Foekens J A; Stoter G; Berns E M
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
British journal of cancer 2001;85(9):1359-67.
2001: Verhoog L C; van den Ouweland A M; Berns E; van Veghel-Plandsoen M M; van Staveren I L; Wagner A; Bartels C C; Tilanus-Linthorst M M; Devilee P; Seynaeve C; Halley D J; Niermeijer M F; Klijn J G; Meijers-Heijboer H
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
European journal of cancer (Oxford, England : 1990) 2001;37(16):2082-90.
2001: Meijer-van Gelder M E; Look M P; Bolt-de Vries J; Peters H A; Klijn J G; Foekens J A
Clinical relevance of biologic factors in male breast cancer.
Breast cancer research and treatment 2001;68(3):249-60.
2001: Berns E M; van Staveren I L; Verhoog L; van de Ouweland A M; Meijer-van Gelder M; Meijers-Heijboer H; Portengen H; Foekens J A; Dorssers L C; Klijn J G
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
British journal of cancer 2001;85(4):538-45.
2001: Meijers-Heijboer H; van Geel B; van Putten W L; Henzen-Logmans S C; Seynaeve C; Menke-Pluymers M B; Bartels C C; Verhoog L C; van den Ouweland A M; Niermeijer M F; Brekelmans C T; Klijn J G
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
The New England journal of medicine 2001;345(3):159-64.
2001: Foekens J A; Peters H A; Grebenchtchikov N; Look M P; Meijer-van Gelder M E; Geurts-Moespot A; van der Kwast T H; Sweep C G; Klijn J G
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Cancer research 2001;61(14):5407-14.
2001: de Witte J H; Foekens J A; Brünner N; Heuvel J J; van Tienoven T; Look M P; Klijn J G; Geurts-Moespot A; Grebenchtchikov N; Benraad T; Sweep C G
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.
British journal of cancer 2001;85(1):85-92.
2001: Foekens J A; Romain S; Look M P; Martin P M; Klijn J G
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Cancer research 2001;61(4):1421-5.
2001: Brekelmans C T; Seynaeve C; Bartels C C; Tilanus-Linthorst M M; Meijers-Heijboer E J; Crepin C M; van Geel A A; Menke M; Verhoog L C; van den Ouweland A; Obdeijn I M; Klijn J G;
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):924-30.
2001: Lodder L; Frets P G; Trijsburg R W; Meijers-Heijboer E J; Klijn J G; Duivenvoorden H J; Tibben A; Wagner A; van der Meer C A; van den Ouweland A M; Niermeijer M F
Psychological impact of receiving a BRCA1/BRCA2 test result.
American journal of medical genetics 2001;98(1):15-24.
2001: van de Wetering M; Barker N; Harkes I C; van der Heyden M; Dijk N J; Hollestelle A; Klijn J G; Clevers H; Schutte M
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.
Cancer research 2001;61(1):278-84.
2001: Kriege M; Brekelmans C T; Boetes C; Rutgers E J; Oosterwijk J C; Tollenaar R A; Manoliu R A; Holland R; de Koning H J; Klijn J G
MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
Familial cancer 2001;1(3-4):163-8.
2000: Lodder L N; Frets P G; Trijsburg R W; Meijers-Heijboer E J; Klijn J G; Niermeijer M F
Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands.
Journal of medical genetics 2000;37(11):883-4.
2000: Verhoog L C; Berns E M; Brekelmans C T; Seynaeve C; Meijers-Heijboer E J; Klijn J G
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21 Suppl):119S-24S.
2000: Klijn J G; Setyono-Han B; Foekens J A
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.
Steroids 2000;65(10-11):825-30.
2000: Kramer J A; Curran D; Piccart M; de Haes J C; Bruning P; Klijn J; Van Hoorebeeck I; Paridaens R
Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(12):1498-506.
2000: Kramer J A; Curran D; Piccart M; de Haes J C; Bruning P F; Klijn J G; Bontenbal M; van Pottelsberghe C; Groenvold M; Paridaens R
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.
European journal of cancer (Oxford, England : 1990) 2000;36(12):1488-97.
2000: Verhoog L C; Brekelmans C T; Seynaeve C; Meijers-Heijboer E J; Klijn J G
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
British journal of cancer 2000;83(3):384-6.
2000: Meijers-Heijboer E J; Verhoog L C; Brekelmans C T; Seynaeve C; Tilanus-Linthorst M M; Wagner A; Dukel L; Devilee P; van den Ouweland A M; van Geel A N; Klijn J G
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Lancet 2000;355(9220):2015-20.
2000: Klijn J G; Beex L V; Mauriac L; van Zijl J A; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
Journal of the National Cancer Institute 2000;92(11):903-11.
2000: Berns E M; Foekens J A; Vossen R; Look M P; Devilee P; Henzen-Logmans S C; van Staveren I L; van Putten W L; Inganäs M; Meijer-van Gelder M E; Cornelisse C; Claassen C J; Portengen H; Bakker B; Klijn J G
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Cancer research 2000;60(8):2155-62.
2000: Hamilton A; Roy J A; Beex L; Piccart M; Mauriac L; Coleman R; Paridaens R; Boes G H; van Vreckem A; Palmer P; Klijn J
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Breast cancer research and treatment 2000;60(2):181-8.
2000: Broeks A; Urbanus J H; Floore A N; Dahler E C; Klijn J G; Rutgers E J; Devilee P; Russell N S; van Leeuwen F E; van 't Veer L J
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.
American journal of human genetics 2000;66(2):494-500.
2000: Foekens J A; Peters H A; Look M P; Portengen H; Schmitt M; Kramer M D; Brünner N; Jänicke F; Meijer-van Gelder M E; Henzen-Logmans S C; van Putten W L; Klijn J G
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Cancer research 2000;60(3):636-43.
2000: Bontenbal M; van Putten W L; Burghouts J T; Baggen M G; Ras G J; Stiegelis W F; Beudeker M; Janssen J T; Braun J J; van der Linden G H; van der Velden P C; van Geel A N; Helle P; Leisink M; Foekens J A; Klijn J G
Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):734-42.
2000: Paridaens R; Biganzoli L; Bruning P; Klijn J G; Gamucci T; Houston S; Coleman R; Schachter J; Van Vreckem A; Sylvester R; Awada A; Wildiers J; Piccart M
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):724-33.
2000: van der Flier S; Brinkman A; Look M P; Kok E M; Meijer-van Gelder M E; Klijn J G; Dorssers L C; Foekens J A
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
Journal of the National Cancer Institute 2000;92(2):120-7.
2000: Peelen T; van Vliet M; Bosch A; Bignell G; Vasen H F; Klijn J G; Meijers-Heijboer H; Stratton M; van Ommen G J; Cornelisse C J; Devilee P
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.
British journal of cancer 2000;82(1):151-6.
1999: Lodder L N; Frets P G; Trijsburg R W; Meijers-Heijboer E J; Klijn J G; Duivenvoorden H J; Tibben A; Wagner A; van der Meer C A; Devilee P; Cornelisse C J; Niermeijer M F
Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
Journal of medical genetics 1999;36(12):906-13.
1999: Verhoog L C; Brekelmans C T; Seynaeve C; Dahmen G; van Geel A N; Bartels C C; Tilanus-Linthorst M M; Wagner A; Devilee P; Halley D J; van den Ouweland A M; Meijers-Heijboer E J; Klijn J G
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3396-402.
1999: Brekelmans C T; Bartels C C; Crepin E; van Geel A N; Meijers-Heijboer H; Seynaeve C; Tilanus-Linthorst M M; Verhoog L C; Wagner A; Klijn J G
Breast cancer screening in high-risk women. Rotterdam Committee of Medical and Genetic Counseling.
Disease markers 1999;15(1-3):34-6.
1999: Sieuwerts A M; Klijn J G; Foekens J A
Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts.
Molecular and cellular endocrinology 1999;154(1-2):179-85.
1999: Foekens J A; Dall P; Klijn J G; Skroch-Angel P; Claassen C J; Look M P; Ponta H; Van Putten W L; Herrlich P; Henzen-Logmans S C
Prognostic value of CD44 variant expression in primary breast cancer.
International journal of cancer. Journal international du cancer 1999;84(3):209-15.
1999: Sieuwerts A M; Klijn J G; Henzen-Logmans S C; Foekens J A
Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro.
Breast cancer research and treatment 1999;55(1):9-20.
1999: Meijer-van Gelder M E; Look M P; Bolt-de Vries J; Peters H A; Klijn J G; Foekens J A
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1449-57.
1999: Brekelmans C T; Voogd A C; Botke G; van Geel B N; Rodrigus P; Rutgers E J; Klijn J G; Coebergh J W
Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST).
European journal of cancer (Oxford, England : 1990) 1999;35(4):620-6.
1999: de Witte J H; Sweep C G; Klijn J G; Grebenschikov N; Peters H A; Look M P; van Tienoven T H; Heuvel J J; Bolt-De Vries J; Benraad T J; Foekens J A
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
British journal of cancer 1999;80(1-2):286-94.
1999: de Witte J H; Sweep C G; Klijn J G; Grebenschikov N; Peters H A; Look M P; van Tienoven T H; Heuvel J J; van Putten W L; Benraad T J; Foekens J A
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
British journal of cancer 1999;79(7-8):1190-8.
1999: Schuyer M; Henzen-Logmans S C; van der Burg M E; Fieret J H; Derksen C; Look M P; Meijer-van Gelder M E; Klijn J G; Foekens J A; Berns E M
Genetic alterations in ovarian borderline tumours and ovarian carcinomas.
European journal of obstetrics, gynecology, and reproductive biology 1999;82(2):147-50.
1999: Foekens J A; Look M P; Bolt-de Vries J; Meijer-van Gelder M E; van Putten W L; Klijn J G
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
British journal of cancer 1999;79(2):300-7.
1998: van Roozendaal C E; Gillis A J; Klijn J G; van Ooijen B; Claassen C J; Eggermont A M; Henzen-Logmans S C; Oosterhuis J W; Foekens J A; Looijenga L H
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures.
FEBS letters 1998;437(1-2):107-11.
1998: Bontenbal M; Sieuwerts A M; Peters H A; van Putten W L; Foekens J A; Klijn J G
Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro.
Breast cancer research and treatment 1998;51(2):139-48.
1998: Bontenbal M; de Wit R; Klijn J G; Seynaeve C
[Chemotherapy in metastasized breast carcinoma]
Nederlands tijdschrift voor geneeskunde 1998;142(30):1709-13.
1998: Bruning P F; Bonfrer J M; Paridaens R; Nooij M; Klijn J G; Beex L V; Bruynseels J; Piccart M J
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Anti-cancer drugs 1998;9(5):419-25.
1998: Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen H T; Klijn J G; van Oosterom A T
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
British journal of cancer 1998;77(12):2257-63.
1998: Sieuwerts A M; Klijn J G; Henzen-Logmand S C; Bouwman I; Van Roozendaal K E; Peters H A; Setyono-Han B; Foekens J A
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
International journal of cancer. Journal international du cancer 1998;76(6):829-35.
1998: Schuyer M; Henzen-Logmans S C; van der Burg M E; Fieret E J; Klijn J G; Foekens J A; Berns E M
High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.
International journal of cancer. Journal international du cancer 1998;76(3):299-303.
1998: Berns E M; van Staveren I L; Look M P; Smid M; Klijn J G; Foekens J A
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
British journal of cancer 1998;77(7):1130-6.
1998: Berns E M; van Staveren I L; Klijn J G; Foekens J A
Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer.
Breast cancer research and treatment 1998;48(1):87-92.
1998: Foekens J A; Kos J; Peters H A; Krasovec M; Look M P; Cimerman N; Meijer-van Gelder M E; Henzen-Logmans S C; van Putten W L; Klijn J G
Prognostic significance of cathepsins B and L in primary human breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1013-21.
1998: Verhoog L C; Brekelmans C T; Seynaeve C; van den Bosch L M; Dahmen G; van Geel A N; Tilanus-Linthorst M M; Bartels C C; Wagner A; van den Ouweland A; Devilee P; Meijers-Heijboer E J; Klijn J G
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Lancet 1998;351(9099):316-21.
1998: Paridaens R; Roy J A; Nooij M; Klijn J; Houston S J; Beex L V; Vinholes J; Tomiak E; Van Vreckem A; Langenaeken C; Van Glabbeke M; Piccart M J
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Anti-cancer drugs 1998;9(1):29-35.
1998: Berns E M; Klijn J G; van Putten W L; de Witte H H; Look M P; Meijer-van Gelder M E; Willman K; Portengen H; Benraad T J; Foekens J A
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):121-7.
1998: Bontenbal M; Foekens J A; Lamberts S W; de Jong F H; van Putten W L; Braun H J; Burghouts J T; van der Linden G H; Klijn J G
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
British journal of cancer 1998;77(1):115-22.
1997: Petrij-Bosch A; Peelen T; van Vliet M; van Eijk R; Olmer R; Drüsedau M; Hogervorst F B; Hageman S; Arts P J; Ligtenberg M J; Meijers-Heijboer H; Klijn J G; Vasen H F; Cornelisse C J; van 't Veer L J; Bakker E; van Ommen G J; Devilee P
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
Nature genetics 1997;17(3):341-5.
1997: Piccart M J; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3149-55.
1997: Berns E M; De Witte H H; Klijn J G; Willman K; Look M P; Meijer-Van Gelder M E; Benraad T J; Foekens J A
Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
Anticancer research 1997;17(4B):3003-6.
1997: Awada A; Van Vreckem A; Paridaens R; Bruning P F; Klijn J; Tomiak E; Vinholes J; Roy J A; Kusenda Z; Hoctin Boes G; Van Glabbeke M; Piccart M J
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1173-6.
1997: DudokdeWit A C; Tibben A; Frets P G; Meijers-Heijboer E J; Devilee P; Klijn J G; Oosterwijk J C; Niermeijer M F
BRCA1 in the family: a case description of the psychological implications.
American journal of medical genetics 1997;71(1):63-71.
1997: Romain S; Martin P M; Klijn J G; van Putten W L; Look M P; Guirou O; Foekens J A
DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer?
International journal of cancer. Journal international du cancer 1997;74(2):156-61.
1997: Frets P G; Dudok de Wit A C; Tibben A; Meijers-Heijboer E J; Klijn J G; Niermeijer M F
[Hereditary breast and/or ovarian cancer: consequences for family relations]
Oncologica / Vereniging van Oncologie Verpleegkundigen 1997;14(1):47-9.
1997: Sieuwerts A M; Klijn J G; Foekens J A
Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane.
Clinical & experimental metastasis 1997;15(1):53-62.
1996: van der Burg M E; Henzen-Logmans S C; Berns E M; van Putten W L; Klijn J G; Foekens J A
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
International journal of cancer. Journal international du cancer 1996;69(6):475-9.
1996: Piccart-Gebhart M J; Bruning P; Gamucci T; Klijn J; Roy J A; Awada A; Kusenda Z; Van Vreckem A; Paridaens R
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Seminars in oncology 1996;23(5 Suppl 11):11-5.
1996: Schuyer M; van Staveren I L; Klijn J G; vd Burg M E; Stoter G; Henzen-Logmans S C; Foekens J A; Berns E M
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
British journal of cancer 1996;74(7):1069-73.
1996: Kuenen-Boumeester V; Van der Kwast T H; Claassen C C; Look M P; Liem G S; Klijn J G; Henzen-Logmans S C
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1560-5.
1996: Berns E M; Klijn J G; Smid M; van Staveren I L; Look M P; van Putten W L; Foekens J A
TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
Genes, chromosomes & cancer 1996;16(3):170-9.
1996: de Witte H H; Foekens J A; Lennerstrand J; Smid M; Look M P; Klijn J G; Benraad T J; Berns E M
Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis.
International journal of cancer. Journal international du cancer 1996;69(2):125-30.
1996: van Roozendaal K E; Klijn J G; van Ooijen B; Claassen C; Eggermont A M; Henzen-Logmans S C; Foekens J A
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources.
International journal of cancer. Journal international du cancer 1996;65(1):120-5.
1996: Klijn J G; Setyono-Han B; Bontenbal M; Seynaeve C; Foekens J
Novel endocrine therapies in breast cancer.
Acta oncologica (Stockholm, Sweden) 1996;35 Suppl 5():30-7.
1995: Sieuwerts A M; Klijn J G; Peters H A; Foekens J A
The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1995;33(11):813-23.
1995: Berns E M; Klijn J G; Smid M; van Staveren I L; Gruis N A; Foekens J A
Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer.
British journal of cancer 1995;72(4):964-7.
1995: Berns E M; Foekens J A; van Staveren I L; van Putten W L; de Koning H Y; Portengen H; Klijn J G
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Gene 1995;159(1):11-8.
1995: Bontenbal M; Planting A S; Verweij J; de Wit R; Kruit W H; Stoter G; Klijn J G
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.
Breast cancer research and treatment 1995;34(2):185-9.
1995: Foekens J A; Look M P; Peters H A; van Putten W L; Portengen H; Klijn J G
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Journal of the National Cancer Institute 1995;87(10):751-6.
1995: Foekens J A; Buessecker F; Peters H A; Krainick U; van Putten W L; Look M P; Klijn J G; Kramer M D
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Cancer research 1995;55(7):1423-7.
1995: van Roozendaal C E; Klijn J G; van Ooijen B; Claassen C; Eggermont A M; Henzen-Logmans S C; Foekens J A
Transforming growth factor beta secretion from primary breast cancer fibroblasts.
Molecular and cellular endocrinology 1995;111(1):1-6.
1995: Berns E M; de Klein A; van Putten W L; van Staveren I L; Bootsma A; Klijn J G; Foekens J A
Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival.
International journal of cancer. Journal international du cancer 1995;64(2):140-5.
1995: Foekens J A; Klijn J G; Natoli C; van Putten W L; Di Stefano P; Look M P; Portengen H; Iacobelli S
Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen.
International journal of cancer. Journal international du cancer 1995;64(2):130-4.
1995: Tilanus-Linthorst M M; Bartels C C; Obdeijn A I; Kuenen-Boumeester V; Klijn J G; Oudkerk M
[Good results in periodic screening in women with increased risk of breast cancer; retrospective study]
Nederlands tijdschrift voor geneeskunde 1995;139(9):445-9.
1995: Klijn J G; Devilee P; van Geel A N; Tilanus-Linthorst M M; Dudok-de Wit C; Meijers-Heijboer E J
[Initial Dutch results with a presymptomatic DNA tests in familial breast/ovarian carcinoma. Rotterdamse Werkgroep voor Erfelijke Tumoren]
Nederlands tijdschrift voor geneeskunde 1995;139(9):439-45.
1995: Oosterwijk J C; Devilee P; Meijers-Heijboer E J; Menko F H; Klijn J G; Cornelisse C J
[Cloning of the first gene for breast/ovarian cancer (BRCA1), mapping of a second gene locus (BRCA2) and consequences for clinical practice]
Nederlands tijdschrift voor geneeskunde 1995;139(9):421-3.
1994: Foekens J A; Portengen H; Look M P; van Putten W L; Thirion B; Bontenbal M; Klijn J G
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
British journal of cancer 1994;70(6):1217-23.
1994: Foekens J A; Schmitt M; van Putten W L; Peters H A; Kramer M D; Jänicke F; Klijn J G
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1648-58.
1994: de Wit A C; Meijers-Heijboer E J; Tibben A; Frets P G; Klijn J G; Devilee P; Niermeijer M F
Effect on a Dutch family of predictive DNA-testing for hereditary breast and ovarian cancer.
Lancet 1994;344(8916):197.
1994: Klijn J G; Setyono-Han B; Sander H J; Lamberts S W; de Jong F H; Deckers G H; Foekens J A
Pre-clinical and clinical treatment of breast cancer with antiprogestins.
Human reproduction (Oxford, England) 1994;9 Suppl 1():181-9.
1994: Henzen-Logmans S C; Fieret E J; Berns E M; van der Burg M E; Klijn J G; Foekens J A
Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
International journal of cancer. Journal international du cancer 1994;57(4):468-72.
1994: Klijn J G; Look M P; Portengen H; Alexieva-Figusch J; van Putten W L; Foekens J A
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.
Breast cancer research and treatment 1994;29(1):73-83.
1993: Klijn J G; de Voogt H J; Studer U E; Schröder F H; Sylvester R; De Pauw M
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Cancer 1993;72(12 Suppl):3858-62.
1993: Klijn J G; Berns P M; Bontenbal M; Foekens J A
Growth factors. Clinical implications in breast cancer.
Annals of the New York Academy of Sciences 1993;698():85-101.
1993: Foekens J A; van Putten W L; Portengen H; de Koning H Y; Thirion B; Alexieva-Figusch J; Klijn J G
Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):899-908.
1993: Klijn J G; Berns E M; Bontenbal M; Foekens J
Cell biological factors associated with the response of breast cancer to systemic treatment.
Cancer treatment reviews 1993;19 Suppl B():45-63.
1993: Foekens J A; Sieuwerts A M; Stuurman-Smeets E M; Peters H A; Klijn J G
Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.
British journal of cancer 1993;67(2):232-6.
1993: van der Burg M E; Henzen-Logmans S C; Foekens J A; Berns E M; Rodenburg C J; van Putten W L; Klijn J G
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study.
European journal of cancer (Oxford, England : 1990) 1993;29A(14):1951-7.
1993: Klijn J G; Berns P M; van Putten W L; Bontenbal M; Alexieva-Figusch J; Foekens J A
Critical review of growth factors as clinical tools in primary and metastatic breast cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;127():77-88.
1992: Henzen-Logmans S C; Berns E M; Klijn J G; van der Burg M E; Foekens J A
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.
British journal of cancer 1992;66(6):1015-21.
1992: Foekens J A; Schmitt M; van Putten W L; Peters H A; Bontenbal M; Jänicke F; Klijn J G
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Cancer research 1992;52(21):6101-5.
1992: Klijn J G; Berns P M; Bontenbal M; Alexieva-Figusch J; Foekens J A
Clinical breast cancer, new developments in selection and endocrine treatment of patients.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):211-21.
1992: Berns E M; Foekens J A; van Putten W L; van Staveren I L; Portengen H; de Koning W C; Klijn J G
Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):13-9.
1992: Berns E M; Klijn J G; Henzen-Logmans S C; Rodenburg C J; van der Burg M E; Foekens J A
Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer.
International journal of cancer. Journal international du cancer 1992;52(2):218-24.
1992: de Koning H J; van Ineveld B M; de Haes J C; van Oortmarssen G J; Klijn J G; van der Maas P J
Advanced breast cancer and its prevention by screening.
British journal of cancer 1992;65(6):950-5.
1992: Foekens J A; Sieuwerts A M; Stuurman-Smeets E M; Dorssers L C; Berns E M; Klijn J G
Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro.
International journal of cancer. Journal international du cancer 1992;51(3):439-44.
1992: Berns E M; Klijn J G; van Putten W L; van Staveren I L; Portengen H; Foekens J A
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Cancer research 1992;52(5):1107-13.
1992: Klijn J G; Berns P M; Schmitz P I; Foekens J A
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.
Endocrine reviews 1992;13(1):3-17.
1992: Berns E M; Klijn J G; van Staveren I L; Portengen H; Foekens J A
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors.
Cancer research 1992;52(4):1036-9.
1992: van Roozendaal C E; van Ooijen B; Klijn J G; Claassen C; Eggermont A M; Henzen-Logmans S C; Foekens J A
Stromal influences on breast cancer cell growth.
British journal of cancer 1992;65(1):77-81.
1992: Bontenbal M; Planting A S; Rodenburg C J; Dees A; Verweij J; Bartels C C; Alexieva-Figusch J; van Putten W L; Klijn J G
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer.
Breast cancer research and treatment 1992;21(2):133-8.
1992: Klijn J G
LH-RH agonists in the treatment of metastatic breast cancer: ten years' experience.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;124():75-90.
1992: Foekens J A; Klijn J G
Direct antitumor effects of LH-RH analogs.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1992;124():7-17.
1992: Berns E M; Klijn J G; van Staveren I L; Portengen H; Noordegraaf E; Foekens J A
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):697-700.
1992: Henzen-Logmans S C; van der Burg M E; Foekens J A; Berns P M; Brussée R; Fieret J H; Klijn J G; Chadha S; Rodenburg C J
Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study.
Journal of cancer research and clinical oncology 1992;118(4):303-7.
1991: Klijn J G; van Geel B; de Jong F H; Sandow J; Krauss B
The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia.
Clinical endocrinology 1991;34(4):253-8.
1991: Klijn J G
Second international symposium on 'Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents'. Meeting report, April 9-11, 1990, Rotterdam, The Netherlands.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(3):183-9.
1990: De Jong F H; Grootenhuis A J; Steenbergen J; van Sluijs F J; Foekens J A; ten Kate F J; Oosterhuis J W; Lamberts S W; Klijn J G
Inhibin immunoreactivity in gonadal and non-gonadal tumors.
The Journal of steroid biochemistry and molecular biology 1990;37(6):863-6.
1990: Bakker G H; Setyono-Han B; Portengen H; De Jong F H; Foekens J A; Klijn J G
Treatment of breast cancer with different antiprogestins: preclinical and clinical studies.
The Journal of steroid biochemistry and molecular biology 1990;37(6):789-94.
1990: Bontenbal M; Sieuwerts A M; Peters H A; Sonneveld P; Foekens J A; Klijn J G
Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1097-101.
1990: Foekens J A; van Putten W L; Portengen H; Rodenburg C J; Reubi J C; Berns P M; Henzen-Logmans S C; van der Burg M E; Alexieva-Figusch J; Klijn J G
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
The Journal of steroid biochemistry and molecular biology 1990;37(6):815-21.
1990: Klijn J G; Setyono-Han B; Bakker G H; van der Burg M E; Bontenbal M; Peters H A; Sieuwerts A M; Berns P M; Foekens J A
Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1089-95.
1990: Bakker G H; Setyono-Han B; Foekens J A; Portengen H; van Putten W L; de Jong F H; Lamberts S W; Reubi J C; Klijn J G
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.
Breast cancer research and treatment 1990;17(1):23-32.
1990: Klijn J G; Hoff A M; Planting A S; Verweij J; Kok T; Lamberts S W; Portengen H; Foekens J A
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
British journal of cancer 1990;62(4):627-30.
1990: Foekens J A; Rio M C; Seguin P; van Putten W L; Fauque J; Nap M; Klijn J G; Chambon P
Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Cancer research 1990;50(13):3832-7.
1990: Klijn J G
Scientific background of hormonal treatment of prostate cancer.
Progress in clinical and biological research 1990;357():7-22.
1989: Foekens J A; Portengen H; van Putten W L; Trapman A M; Reubi J C; Alexieva-Figusch J; Klijn J G
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.
Cancer research 1989;49(24 Pt 1):7002-9.
1989: Bontenbal M; Sieuwerts A M; Klijn J G; Peters H A; Krijnen H L; Sonneveld P; Foekens J A
Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.
British journal of cancer 1989;60(5):688-92.
1989: Foekens J A; Portengen H; van Putten W L; Peters H A; Krijnen H L; Alexieva-Figusch J; Klijn J G
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
Cancer research 1989;49(21):5823-8.
1989: Bakker G H; Setyono-Han B; Portengen H; De Jong F H; Foekens J A; Klijn J G
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Endocrinology 1989;125(3):1593-8.
1989: Klijn J G; de Jong F H; Bakker G H; Lamberts S W; Rodenburg C J; Alexieva-Figusch J
Antiprogestins, a new form of endocrine therapy for human breast cancer.
Cancer research 1989;49(11):2851-6.
1988: Lamberts S W; Uitterlinden P; Schuijff P C; Klijn J G
Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'.
Clinical endocrinology 1988;29(4):411-20.
1988: Bontenbal M; Sonneveld P; Foekens J A; Klijn J G
Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7).
European journal of cancer & clinical oncology 1988;24(9):1409-14.
1988: Alexieva-Figusch J; Van Putten W L; Blankenstein M A; Blonk-Van Der Wijst J; Klijn J G
The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
Cancer 1988;61(4):758-68.
1987: Bakker G H; Setyono-Han B; Henkelman M S; de Jong F H; Lamberts S W; van der Schoot P; Klijn J G
Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Cancer treatment reports 1987;71(11):1021-7.
1987: van der Schoot P; Bakker G H; Klijn J G
Effects of the progesterone antagonist RU486 on ovarian activity in the rat.
Endocrinology 1987;121(4):1375-82.
1987: Lamberts S W; Klijn J G; de Jong F H
The definition of true recurrence of pituitary-dependent Cushing's syndrome after transsphenoidal operation.
Clinical endocrinology 1987;26(6):707-12.
1985: Alexieva-Figusch J; Van Putten W L; van Gilse H A; Blonk-vd Wijst J; Klijn J G
Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study).
Medical oncology and tumor pharmacotherapy 1985;2(2):69-75.
1984: Alexieva-Figusch J; Blankenstein M A; Hop W C; Klijn J G; Lamberts S W; de Jong F H; Docter R; Adlercreutz H; van Gilse H A
Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.
European journal of cancer & clinical oncology 1984;20(1):33-40.
1984: Klijn J G; de Jong F H; Blankenstein M A; Docter R; Alexieva-Figusch J; Blonk-van der Wijst J; Lamberts S W
Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
Breast cancer research and treatment 1984;4(3):209-20.
1980: Lamberts S W; Klijn J G; de Jong F H; Birkenhäger J C
Differences in secretion characteristics in Cushing's disease with and without radiologically evident pituitary tumors.
Journal of endocrinological investigation 1980;3(3):257-62.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jan Klijn

Research Profile (preview)

Disorders

Genes & Molecular Sequences

Chemicals & Drugs

Concepts & Ideas

Physiology

Geographic Areas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jan Klijn (preview)

All Publications